Bill > SB465

This bill classifies xylazine, a veterinary sedative and muscle relaxant that has recently been associated with the opioid crisis, as a Schedule III controlled drug in New Hampshire. By amending the state's Controlled Drug Act (RSA 318-B), the legislation specifically adds a new section that places xylazine under Schedule III classification, bypassing the typical rulemaking process by the Department of Health and Human Services. The bill is set to take effect on January 1, 2027, which gives state agencies and stakeholders time to prepare for the new classification. While the fiscal note indicates no direct revenue impact, it acknowledges potential indeterminable expenditures for the state, counties, and local governments due to potential changes in law enforcement, judicial, and correctional system processes related to the drug's new controlled substance status. The bill reflects growing concerns about xylazine's role in the drug epidemic, particularly its use as an adulterant in illicit drug supplies that can increase overdose risks.

Justice

https://gc.nh.gov/bill_Status/billinfo.aspx?id=1191&inflect=2